Andrew Walker

Andrew Walker is a Director at Salus Alba, a consultancy specializing in health technology assessment (HTA) and pharmaeconomics, which he founded in 2015. His background includes significant experience in health economics, having previously worked as a reviewer at the Scottish Medicines Consortium (SMC) and with an Evidence Review Group at NICE. Walker has a strong academic foundation, having been involved in various roles within academia and local payer organizations, including a position at Glasgow University where he helped establish review systems for new medicine submissions.13

His expertise particularly focuses on market access for pharmaceutical companies, with a notable emphasis on rare disease medicines, which constitute a substantial portion of his consultancy work. He has been involved in projects concerning treatments for conditions like Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA) among others.13

Walker holds a Master’s and a PhD, and his educational background includes studies at the University of Nottingham.2 His extensive experience and contributions to the field make him a key figure in the healthcare consultancy landscape in the UK.